Charlie W Lees

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2745676/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. Gut, 2023, 72, 410-412.	12.1	5
2	What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease?. Clinical Gastroenterology and Hepatology, 2022, 20, 468-469.	4.4	1
3	Prediction of Relapse After Anti–Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. Clinical Gastroenterology and Hepatology, 2022, 20, 1671-1686.e16.	4.4	15
4	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. Journal of Crohn's and Colitis, 2022, 16, 389-397.	1.3	39
5	Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology, 2022, 162, 1456-1475.e1.	1.3	38
6	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. The Lancet Gastroenterology and Hepatology, 2022, 7, 342-352.	8.1	100
7	Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis. Alimentary Pharmacology and Therapeutics, 2022, 56, 67-76.	3.7	7
8	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nature Communications, 2022, 13, 1379.	12.8	48
9	Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. Lancet Rheumatology, The, 2022, 4, e490-e506.	3.9	61
10	Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 1835-1844.e6.	4.4	26
11	Are we addressing the top 10 research priorities in IBD?. Frontline Gastroenterology, 2021, 12, 564-569.	1.8	6
12	The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. Inflammatory Bowel Diseases, 2021, 27, 451-457.	1.9	31
13	COVID-19 and IBD drugs: should we change anything at the moment?. Gut, 2021, 70, 632-634.	12.1	11
14	The Impact of <i>NOD2</i> Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. Journal of Crohn's and Colitis, 2021, 15, 800-812.	1.3	22
15	P123â€Are we addressing the top ten research priorities in management of IBD in the UK?. , 2021, , .		0
16	P109â€Vedolizumab is an effective treatment for antibiotic refractory chronic pouchitis. , 2021, , .		0
17	Analysis of colectomy rates for ulcerative colitis in pre―and postbiological eras in Lothian, Scotland. Colorectal Disease, 2021, 23, 1175-1183.	1.4	10
18	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 2021, 70, 865-875.	12.1	153

CHARLIE W LEES

#	Article	IF	CITATIONS
19	Realâ€world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2067-2075.	2.8	17
20	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. The Lancet Gastroenterology and Hepatology, 2021, 6, 218-224.	8.1	111
21	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 2021, 70, 1884-1893.	12.1	233
22	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. The Lancet Gastroenterology and Hepatology, 2021, 6, 271-281.	8.1	23
23	Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-NaÃ⁻ve SB5 Observational Cohorts. Journal of Crohn's and Colitis, 2021, 15, 2011-2021.	1.3	20
24	SARS-CoV-2 vaccination for patients with inflammatory bowel disease – Authors' reply. The Lancet Gastroenterology and Hepatology, 2021, 6, 523-524.	8.1	2
25	PMO-49â€Patient perceptions about causes of flare in IBD: baseline results from the PREdiCCt study. , 2021, , .		0
26	Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110547.	3.2	4
27	Mobile Health in IBD: Enhancing Care, One Phone at a Time. Inflammatory Bowel Diseases, 2020, 26, 163-166.	1.9	4
28	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 526.	4.4	0
29	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	1.3	249
30	Paediatric Patients (Less Than Age of 17 Years) Account for Less Than 1.5% of All Prevalent Inflammatory Bowel Disease Cases. Journal of Pediatric Gastroenterology and Nutrition, 2020, 71, 521-523.	1.8	15
31	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. BMC Medical Genetics, 2020, 21, 204.	2.1	11
32	Environmental stimuli and gut inflammation via dysbiosis in mouse and man. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 715-716.	17.8	2
33	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. Frontline Gastroenterology, 2020, 11, 343-350.	1.8	37
34	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. United European Gastroenterology Journal, 2020, 8, 1076-1085.	3.8	35
35	Innovation in Inflammatory Bowel Disease Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease. Gastroenterology, 2020, 159, 805-808.e1.	1.3	54
36	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	12.1	28

CHARLIE W LEES

#	Article	IF	CITATIONS
37	Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. Frontline Gastroenterology, 2020, 11, 117-123.	1.8	9
38	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	1.3	185
39	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	12.1	232
40	Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 2269-2276.e4.	4.4	48
41	IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology. Gut, 2019, 68, 1953-1960.	12.1	134
42	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
43	OWE-04â€A capture-recapture study of all-age IBD point prevalence in scotland. , 2019, , .		2
44	Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. Inflammatory Bowel Diseases, 2019, 25, 1036-1043.	1.9	19
45	Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. Digestive Diseases and Sciences, 2019, 64, 1660-1667.	2.3	25
46	IBD Genomic Risk Loci and Overlap with Other Inflammatory Diseases. , 2019, , 91-115.		0
47	The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease. Inflammatory Bowel Diseases, 2018, 24, 583-592.	1.9	40
48	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. Gastroenterology, 2018, 154, 1320-1333.e10.	1.3	116
49	PWE-026â€Endoscopy is superior to stool frequency in predicting response to steroids in acute ulcerative colitis. , 2018, , .		0
50	PWE-019â€Day of admission results predict outcome in acute ulcerative colitis. , 2018, , .		0
51	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nature Genetics, 2017, 49, 256-261.	21.4	943
52	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. Nature Genetics, 2017, 49, 186-192.	21.4	153
53	Fine-mapping inflammatory bowel disease loci to single-variant resolution. Nature, 2017, 547, 173-178.	27.8	473
54	Bilateral lower limb weakness in acute severe ulcerative colitis. Lancet, The, 2016, 388, 101-102.	13.7	7

CHARLIE W LEES

#	Article	IF	CITATIONS
55	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet, The, 2016, 387, 156-167.	13.7	607
56	The Impact of Different DNA Extraction Kits and Laboratories upon the Assessment of Human Gut Microbiota Composition by 16S rRNA Gene Sequencing. PLoS ONE, 2014, 9, e88982.	2.5	236
57	Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50years. Journal of Crohn's and Colitis, 2014, 9, 41-9.	1.3	43
58	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	21.4	165
59	Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	27.8	4,038
60	Guidelines for the management of inflammatory bowel disease in adults. Gut, 2011, 60, 571-607.	12.1	1,127
61	Genetics of ulcerative colitis. Inflammatory Bowel Diseases, 2011, 17, 831-848.	1.9	133
62	Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case–control study. Inflammatory Bowel Diseases, 2011, 17, 937-946.	1.9	21
63	Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert Review of Gastroenterology and Hepatology, 2009, 3, 513-534.	3.0	78
64	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics, 2008, 40, 710-712.	21.4	403
65	Early combined immunosuppression in Crohn's disease. Lancet, The, 2008, 371, 1995.	13.7	3
66	Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways. PLoS Medicine, 2008, 5, e239.	8.4	63
67	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics, 2007, 39, 830-832.	21.4	1,063
68	The Hedgehog Signalling Pathway in the Gastrointestinal Tract: Implications for Development, Homeostasis, and Disease. Gastroenterology, 2005, 129, 1696-1710.	1.3	100